New drug cocktail aims to shrink upper tract cancer before surgery
NCT ID NCT05775471
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether giving two drugs—pembrolizumab and enfortumab vedotin—before and after surgery can improve outcomes for people with high-risk upper tract urothelial cancer. The drugs are designed to help the immune system attack cancer cells and deliver a targeted toxin to them. The study will enroll 21 participants and measure how many patients have their tumors shrink or disappear after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pembrolizumab and enfortumab vedotin
- What this could lead to
- If successful, this combination could shrink tumors before surgery and reduce the chance of cancer returning after surgery.
- What could go wrong
- This is a small, early-phase trial with only 21 participants. The drugs may cause side effects, and it is not yet known if they will improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL PELVIS AND URETER UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.